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ENHANCEMENT OF DINITROCHLOROBENZENE (DNCB)
CONTACT SENSITIZATION BY CYCLOPHOS-
PHAMIDE IN THE GUINEA PIG*
HENRY C. MAGUIRE, JR., M.D.t n VON L. ETTOREtt
We have reported that cyclophosphamide (a
nitrogen mustard) functions as immunological
inhibitor in the guinea pig (1—3). Appropriately
timed and in a sufficient amount, cyclophospha-
mide prevents the primary antibody response to
a protein antigen, and guinea pigs so prepared
show immunological unresponsiveness to that
protein, but not to unrelated antigens (drug-in-
duced specific immunological tolerance). Fur-
ther, Salvin has shown that guinea pigs made
tolerant with cyclophosphainide are relatively
incapable of acquiring delayed hypersensitivity,
of the Jones-Mote type, to that same protein
(4, 5). Methotrexate also blocks the acquisition
of delayed hypersensitivity, as well as the pri-
mary antibody response, to specific protein in
the guinea pig (6).
The effect of cancer chemotherapeutic drugs
on delayed allergy to simple chemicals has been
studied in the guinea pig (7—9). Both cyclophos-
phamide and methotrexate block the acquisition
of allergic contact dermatitis during the period
of their administration; however, the drug-
treated guinea pigs become permanently sensi-
tive as soon as drug is stopped. Treatment with
methotrexate or cyclophosphamide of guinea
pigs already sensitive to DNCB does not abolish
their hypersensitivity (7, 9).
In past studies it seemed that the ultimate
DNCB challenge reactions of cyclophosphamide-
suppressed guinea pigs might be even more
intense and prolonged than those of control
animals. This would certainly have been a para-
doxical consequence of administering an im-
munosuppressive drug. However, our studies
reported herein demonstrate that cyclophos-
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phamide treatment does, indeed, greatly enhance
the final DNCB challenge responses.
METHODS
Experimental animals were Hartley strain albino
guinea pigs weighing approximately 400 gm. and
purchased from a local animal supplier (Hunting-
don Farms, Incorporated, 1910 West Atlantic
Street, Philadelphia, Pennsylvania 19140). Cyclo-
phosphamide (Cytoxan®) was freshly prepared
and injected intraperitoneally daily for 5 days. On
day 5, the guinea pigs were topically sensitized by
the application of 0.5 mg DNCB in acetone to a
pre-sacral area 2 cm in diameter. Ten days later
(day 15) the guinea pigs were challenged with
DNCB/acetone solutions of the following concen-
trations: 0.1%, 0.05%, 0.025%, and 0.0125%; 0.02
ml of these solutions, as well as 0.02 ml of a 0.1%
croton oil/acetone solution, were pipetted onto 1
cm diameter pm-marked areas on the flanks of the
guinea pigs. Reactions were read at 24, 48, and 72
hours. Sensitization and challenge sites had been
Zip® wax-epilated several days prior to DNCB
application. The cyclophosphamide-treated guinea
pigs developed a transient leukopenia, but by the
time of challenge their white blood counts had re-
turned to normal.
The experimental design is outlined in Figure 1,
and the results are set down in Table I. The meth-
ods are similar to those of previous studies (10,
11).
RESULTS
The DNCB challenge responses of the experi-
mental group were qualitatively more intense
and more prolonged (Table I). There were no
significant differences between the croton oil re-
actions of the two groups. We have obtained
comparable results using paraphenylenediamine
as sensitizer.
CONCLUSIONS
Generally, whole body x-ray and the cancer
chemotherapeutic drugs suppress primary anti-
body formation and the acquisition of delayed
hypersensitivity (12—14). There is considerable
species variation in the inhibitory effect of the
t Supplied through the kindness of Dr. Max
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different drugs. For instance, while 6-mercapto-
purine profoundly suppresses antibody produc-
tion in the rabbit, that drug has but negligible
effect on antibody formation in the guinea pig
(15, 16).
However, several investigators have so timed
their antigen as to enhance primary antibody
formation with whole body x-ray (17, 18). Here,
the time relation between antigen and x-ray is
crucial and unique for each antigen. For in-
stance, using soluble bovine gamma globulin as
antigen in rabbits, Dixon and McConahey found
that x-ray 2 hours after antigen did not affect
antibody formation, whereas there was consider-
able enhancement if x-ray were given 1, 2, or
21/2 days after antigen; the 2½ day post-antigen
x-ray resulted in the maximum primary anti-
body response (16). The mechanism of this
x-ray enhancement is obscure. More recently,
Schwartz et at have reported that 6-mercapto-
purine which can produce specific immune toler-
ance in the rabbit, in that same animal, in-
creased primary antibody formation when
antigen was given after the course of 6-mercap-
topurine (19, 20). Enhanced antibody formation
resulting from appropriately timed Actinomycin
D, Actinomycin C, colchicine, Colcernid®, and
5-fluoro-2-deoxyuridine in different animals has
been described (21—26).
Ordinarily, cyclophosphamide inhibits the ac-
quisition of delayed hypersensitivity in the
guinea pig. However, we have now demonstrated
that cyclophosphoamide may also perform as
immunological adjuvant and produce precisely
the reverse effect: exaggerated hypersensitivity.
It seems likely that whole body x-ray as well as
other of the immunosuppressive cancer chemo-
therapeutic drugs can be so manipulated as to
enhance the acquisition of allergic contact der-
matitis (27).
The mechanism by which cyclophosphamide
enhances the acquisition of DNCB contact der-
matitis is unclear. Trophic factors have been
described for lymphoid tissue (28). It may be
that these factors are immunotrophic as well as
lymphotrophic, and thereby lead to an inimu-
nologically more efficient processing of simple
chemical and other allergens. Certainly, the
rapid and seemingly complete restoration of
lymphoid tissue after near-complete destruction
by cyclophosphamide (or x-ray) is impressive
and implies a sensitive and dynamic homeostasis
of lymphoid tissue. It would be surprising if
these regulatory mechanisms did not impor-
tantly direct the immunological performance of
lymphoid tissue. On this basis we would predict
that diverse treatments having the common re-
sult of depression followed by regeneration of
lymphoid tissue could enhance the hypersensi-
tivity response. Such potential immunological
adjuvants would include heterologous antilym-
phocyte sera, glucosteroids and certain viruses,
as well as whole body x-ray and many of the
cancer chemotherapeutic drugs.
*1** *
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Fia. 1. Guinea pigs were injected with 10 mg cyclophosphamide intraperitoneally dailyfor 5 days. On day 5, they were topically sensitized with ½ mg DNCB in acetone. Ten
days later the guinea pigs were challenged with graded concentrations of DNCB, as well
as with croton oil. Sensitization and challenge sites of the test animals had been Zip® wax-
epilated several days prior to DNCB application.
TABLE I
24 Hours
Animal number* DNCB 0.1% DNCB 0.05% DNCB 0.025% DNCB 0.0125% Croton oil 0.1%
I
II
III
IV
V
VI
VII
VIII
IX
X
XI
XII
XIII
XIV
XV
XVI
XVII
XVIII
XIX
XX
XXI
XXII
XXIII
XXIV
2+
2+
2+
2+
2+
2+
2+
2+
2+
2+
2+
2+
2+
Trace
2+
2+
1+
Negative
Negative
Trace
Negative
Negative
Negative
Negative
2+
2+
2+
2+
2+
2+
2+
2+
2+
2+
2+
2+
2+
Trace
2+
2+
1+
Negative
Negative
Trace
Negative
Negative
Negative
Negative
Negative
Trace
2+
1+
Trace
2+
Negative
1+
2+
Negative
1+
1+
Negative
Trace
2+
1+
1+
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Trace
Negative
Negative
Negative
Negative
Negative
Trace
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
2+
1+ (weak)
2+ (strong)
2+ (strong)
3+ (strong)
3+
Trace (weak)
2+
2+
2+ (weak)
3+
2+
1+
2+
2+
2+
2+
2+ (weak)
3+ (strong)
Trace (strong)
1+
1+
2+
2+
48 Hours
Animal number DNCB 0.1% DNCB 0.05% DNCB 0.025% DNCB 0.0125%
I
II
III
IV
V
VI
VII
VIII
IX
X
XI
XII
XIII
XIV
XV
XVI
XVII
XVIII
XIX
XX
XXI
XXII
XXIII
XXIV
2+ 1+ Negative
2+ 1+ Negative
1+ 1+ 1+ Negative
1+ 1+ Trace Negative
2+ 1+ Trace Negative
2+ 2+ Trace Negative
Trace Trace Negative
2+ 1+ Trace Negative
2+ 2+ Trace Negative
2+ 1+ Negative
2+ 2+ 1+ Negative
2+ 2+ Trace Negative
Negative
Negative
Trace Trace Negative —
Trace Trace Trace Negative
Negative
Negative —,
Negative —
Negative
Negative —.4
Negative
Negative
Negative — —
41
42 THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
TABLE I—Continued
72 Hours
Animal number DNCB 0.1% DNCB 0.05% DNCB 0.025% DNCB 0.0125%
I 2+ Negative —--+
II
III
2+
Trace
Negative >
Negative .—÷
IV
V
1+
2+
Negative .—
Negative —
VI
VII
VIII
1+ Negative
Negative
2+ Negative
—*
—*
IX
X
1+ Negative
2+ Negative
—*
—*
XI
XII
2+ Negative
Negative >
XIII
XIV
Negative—
Negative
—+
—4
XV
XVI
Negative
Negative
—÷
.—*
XVII
XVIII
Negative —
Negative -.—+
XIX
XX
Negative
Negative
....+
..÷
XXI
XXII
Negative
Negative —*
XXIII
XXIV
Negative
Negative
>
—+
* Animals "I" to "XII" received cyclophosphamide; animals "XIII" to "XXIV" were controls.
Challenge Reactions
Reactions were read at 24,48, and 72 hours and graded according to the following criteria: Negative—
no definite reaction; trace—less than 25% erythema; 1+—25% to 80% erythema; 2+—greater than
80% erythema and/or edema; 3+—exudation. Meaningful readings on the rapidly evolving croton oil
reactions could be made only at 24 hours.
SIJMMARY
Guinea pigs received a S day course of cyclo-
phosphamide, and on day 5 were topically sen-
sitized to dinitrochlorobenzene (DNCB). The
DNCB challenge reactions of these guinea pigs
were exaggerated and prolonged. This represents
a paradoxical effect, since cyclophosphamide is
a well-established immunological inhibitor in the
guinea pig.
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